<DOC>
	<DOCNO>NCT02958163</DOCNO>
	<brief_summary>This multicentre phase II randomize control open-label trial . It compare 6-months objective response ( CR+PR ) rate obtain Drug Eluting Bead Trans-Arterial Chemo-Embolization ( DEB-TACE ) alone versus DEB-TACE follow Stereotactic Ablative Radiotherapy ( SABR ) patient hepatocarcinoma stage BCLC B . This trial also include one substudy . This substudy confront immuno-histochemical result collect tumoral biopsy biological imaging ( MRI ) result . Every patient participate trial also participate substudy .</brief_summary>
	<brief_title>Clinical Trial Comparing TACE With TACE + SABR Stage BCLC B HCC ( HepSTAR )</brief_title>
	<detailed_description>The patient randomize 2 arm determine treatment receive : Arm A : actual standard treatment = TACE Arm B : experimental arm = TACE + SABR</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>Hepatocellular carcinoma large 3 cm nonresectable , diagnosis establish either : dynamic imaging ( noninvasively ) , show typical contrast enhancement washout histopathology satellite lesion allow ( three lesion ) long dos constraint still achievable Hepatocellular carcinoma belong Barcelona Clinic Liver Cancer Stage System class B Tumor must measurable multiphase MRI accord mRECIST criterion Nontumoral liver volume ≥ 800 cc ChildPugh ( CP ) A B7 cirrhosis HCC Patients include require treatment prior liver transplantation ECOG performance status 01 AST/ALT &lt; 5 time ULN Initial platelet ≥ 50 000 x 10E9/l , neutrophil &gt; 1500 x 10E9/l , Hb &gt; 9 g/dl Serum creatinine &lt; 1.5 X normal , calculated Creatinine clearance rate ≥ 60 mL/min As tumor biopsy perform inclusion , pure hepatocellular carcinoma also mixed hepatocellular carcinoma allow trial . Cholangiocarcinoma include . Written inform consent form sign , Patient willing able comply followup schedule Patients fertile age use contraceptive method treatment 4 month . Eligibility resection ablative treatment Extra hepatic spread disease Previous treatment lesion TACE Previous treatment selective internal radiotherapy radiotherapy upper abdomen Uncontrolled Ascites Uncontrolled Encephalopathy Any clinical sign acute viral nonviral hepatitis ( new serological testing require ) Known current pregnancy Uncontrolled active comorbidity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatocellular cancer</keyword>
	<keyword>Stereotactic Body Radiotherapy</keyword>
	<keyword>Chemoembolization , Therapeutic</keyword>
</DOC>